Investment in Isomorphic Labs is money well spent. Thanks to its revolutionary IsoDDE system, it can search chemical spaces for therapeutic and treatment advances that no human team could cover. Positive preclinical results in oncology and immunology show the models already deliver better molecules, opening the door to medical breakthroughs.
The rapid rise in Isomorphic Labs' valuation speaks volumes about the tech bubble, but little about biotech reality. After all, how can people believe a preclinical company with no clinical trials is worth the same as drugmakers pulling in billions in annual revenue? Investors piling in their cash are taking a massive risk based on minimal substance.
© 2026 Improve the News Foundation.
All rights reserved.
Version 8.0.0